Quality Systems – Page 34

System access control failure during system upgrades – inspection evidence pack preparation

Addressing System Access Control Failures During System Upgrades: An Investigation Framework In pharmaceutical manufacturing, the integrity of data and systems is paramount, particularly during system upgrades. A common issue that…

Artwork change error during scale-up – inspection evidence expectations

Addressing Artwork Change Errors during Scale-Up: Ensuring Regulatory Compliance Artwork change errors during the scale-up process in pharmaceutical operations pose significant risks to product quality, regulatory compliance, and patient safety.…

Case processing backlog during signal review – regulatory enforcement risk and mitigation

Managing Case Processing Backlogs in Signal Review: Investigation and Mitigation Strategies In the pharmaceutical industry, the ability to effectively process adverse event cases during signal review is critical to ensuring…

Container closure integrity risk during development – regulatory risk analysis and mitigation

Mitigating Container Closure Integrity Risks During Development: An Investigation Approach Container closure integrity (CCI) is a pivotal aspect in the pharmaceutical sector, particularly during the packaging development phase. A compromise…

Literature surveillance failure during inspection – CAPA for PV system weaknesses

Addressing Failures in Literature Surveillance During Inspection: A CAPA Approach In the pharmaceutical sector, effective pharmacovigilance (PV) is crucial, with literature surveillance serving as a significant component in monitoring drug…

Artwork change error during market launch – how to prevent recall triggers

Addressing Artwork Change Errors During Market Launch to Mitigate Recall Triggers Artwork change errors can have significant implications for pharmaceutical companies, especially during critical phases such as market launches. Such…

Periodic report inconsistencies during signal review – preventing repeat PV findings

Addressing Inconsistencies in Periodic Reports During Signal Review to Prevent Future PV Findings Periodic reports are integral to pharmacovigilance, and inconsistencies within these documents can lead to regulatory scrutiny and…

Artwork change error during inspection readiness – regulatory risk analysis and mitigation

Analyzing Artwork Change Errors During Inspection Readiness: A Practical Approach to Regulatory Risk Management In the pharmaceutical industry, the integrity of product labeling and artwork is critical to compliance, patient…

AE reporting non-compliance during post-marketing surveillance – how to strengthen benefit–risk documentation

Addressing Non-Compliance in AE Reporting During Post-Marketing Surveillance: An Investigative Approach The pharmaceutical industry faces stringent requirements around adverse event (AE) reporting during post-marketing surveillance, a critical component in evaluating…

Tag: Quality Systems